Kura Oncology to Host Virtual Investor Event on KOMET-007 Trial of Ziftomenib Following ASH Annual Meeting
Kura Oncology to Host Virtual Investor Event on KOMET-007 Trial of Ziftomenib Following ASH Annual Meeting
The live webcast can be accessed through Kura Oncology's website and in the Investors section shortly before the event.Kura Oncology will host a virtual investor event on December 9 to discuss ziftomenib's clinical trial updates.
Kura Oncology將於12月9日舉辦虛擬投資者活動，討論ziftomenib的臨床試驗更新。
Quiver AI Summary
Quiver AI 概要
Kura Oncology, Inc. announced a virtual investor event set for December 9, 2024, at 8:00 a.m. ET to discuss its KOMET-007 clinical trial for the oral menin inhibitor, ziftomenib, following new data presented at the ASH Annual Meeting. The event will feature the management team and trial investigators, and interested parties can join via phone or webcast. Kura's pipelines focus on precision medicines for cancer, with ziftomenib recognized by the FDA as a Breakthrough Therapy for a specific type of leukemia. The company has also entered a global collaboration with Kyowa Kirin for ziftomenib's development and is planning a New Drug Application submission in 2025. Other drug candidates are in various stages of clinical trials for different cancers.
Kura oncology公司宣佈將於2024年12月9日上午8:00舉行虛擬投資者活動，討論口服Menin抑制劑ziftomenib的KOMEt-007臨床試驗最新數據，這些數據是在ASH年會上展示的。活動將邀請管理團隊和試驗研究員參加，有興趣的方可以通過電話或網絡直播參與。Kura的產品線側重於癌症的精準醫療，其ziftomenib被FDA認可爲特定類型白血病的突破性療法。公司還與協和麒麟全球合作開發ziftomenib，並計劃在2025年提交新藥申請。其他藥物候選品正在爲不同的癌症進行臨床試驗。
Potential Positives
潛在的積極因素
- The announcement of a virtual investor event demonstrates Kura Oncology's commitment to transparency and engagement with stakeholders regarding its clinical developments.
- Ziftomenib has received Breakthrough Therapy Designation from the FDA, highlighting its potential significance in the treatment of relapsed/refractory NPM1-mutant acute myeloid leukemia.
- The global strategic collaboration agreement with Kyowa Kirin for ziftomenib indicates strong industry partnerships, potentially enhancing development and commercialization efforts.
- Completion of enrollment in the Phase 2 registration-directed trial of ziftomenib positions the company well for a New Drug Application submission anticipated in 2025, suggesting progress in their drug development pipeline.
- Kura Oncology宣佈舉辦虛擬投資者活動，展示了其在臨床發展方面與利益相關者交流透明度和參與度的承諾。
- FDA已授予ziftomenib突破性療法認定，凸顯其在治療復發/難治性NPM1基因突變急性髓樣白血病中的潛在重要性。
- 與協和麒麟達成的全球戰略合作協議爲ziftomenib標誌着強大的行業合作伙伴關係，有望增強開發和商業化工作。
- 完成ziftomenib第2期註冊導向試驗的招募，爲預期在2025年提交新藥申請的公司提供了良好的定位，表明其藥物開發管線取得了進展。
Potential Negatives
潛在負面影響
- The announcement of a virtual investor event may indicate a lack of in-person engagement opportunities, which can be perceived as a weakness in corporate transparency and stakeholder communication.
- The timing of the event, shortly after the ASH Annual Meeting, could suggest that the company is attempting to manage expectations regarding the reception and implications of their clinical data.
- While Kura announced a strategic collaboration with Kyowa Kirin, the partnership might raise concerns regarding reliance on external companies for development and commercialization efforts, potentially impacting the company's control over its pipeline.
- 虛擬投資者活動的公告可能表明缺少面對面參與機會，這可能被視爲公司透明度和利益相關者溝通方面的弱點。
- 活動時間緊隨ASH年會之後，可能暗示公司試圖管理對其臨床數據接受和影響的預期。
- 雖然kura oncology宣佈與京都製藥的戰略合作，但該合作可能引發對依賴外部公司進行開發和商業化努力的擔憂，可能影響公司對其產品線的控制。
FAQ
常見問題
What is the date and time of Kura Oncology's virtual investor event?
Kura Oncology的虛擬投資者活動日期和時間是什麼？
Kura Oncology's virtual investor event is scheduled for December 9, 2024, at 8:00 a.m. ET / 5:00 a.m. PT.
kura oncology虛擬投資者活動定於2024年12月9日上午8:00 Et / 上午5:00 Pt。
How can I access the live webcast for the KOMET-007 trial discussion?
我如何訪問KOMEt-007試驗討論的現場網絡廣播？
The live webcast can be accessed through Kura Oncology's website and in the Investors section shortly before the event.
可以通過kura oncology的網站訪問現場網絡直播，並在活動開始前不久進入投資者部分。
What is ziftomenib, and what is its significance?
ziftomenib是一種口服的、選擇性的menin抑制劑，也是第一種被授予突破治療標誌的調查性治療，用於復發/難治性NPM1突變AML，其意義是什麼？
Ziftomenib is an oral, selective menin inhibitor and the first investigational therapy with Breakthrough Therapy Designation for relapsed/refractory NPM1-mutant AML.
ziftomenib是一種口服的、選擇性的menin抑制劑，也是第一種被授予突破治療標誌的調查性治療，用於復發/難治性NPM1突變AML。
What clinical trials is Kura conducting with ziftomenib?
Kura正在進行哪些臨床試驗，以評估ziftomenib？
Kura is conducting trials to evaluate ziftomenib in various settings, including combination therapies for newly diagnosed and relapsed/refractory AML.
Kura正在進行試驗，評估ziftomenib在各種情境下的應用，包括新診斷和復發/難治性AML的聯合療法。
Who can I contact for investor relations at Kura Oncology?
誰可以聯繫Kura oncology的投資者關係？
You can contact Pete De Spain, Executive Vice President, Investor Relations, at (858) 500-8833 or pete@kuraoncology.com.
您可以聯繫Pete De Spain，執行副總裁，投資者關係，電話：(858) 500-8833，或郵箱：pete@kuraoncology.com。
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
免責聲明：這是由GlobeNewswire分發的新聞稿的人工智能生成摘要。用於總結這份稿件的模型可能會出錯。請在這裏查看完整發布。
$KURA Insider Trading Activity
kura oncology內幕交易活動
$KURA insiders have traded $KURA stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
kura oncology內部人士在過去6個月中已經進行了1次開放市場交易。其中，有0次購買和1次銷售。
Here's a breakdown of recent trading of $KURA stock by insiders over the last 6 months:
這是$KURA股票內部人員在過去6個月中最近交易的詳細情況:
- KATHLEEN FORD (Chief Operating Officer) sold 526 shares.
- KATHLEEN FORD（首席營運官）賣出了526股。
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
要跟蹤內部交易，請查看Quiver Quantitative的內部交易特斯拉-儀表。
$KURA Hedge Fund Activity
kura oncology對沖基金活動
We have seen 81 institutional investors add shares of $KURA stock to their portfolio, and 86 decrease their positions in their most recent quarter.
我們已經看到81家機構投資者在他們的投資組合中增加了$KURA股票的持股，而86家在最近一個季度減少了它們的持倉。
Here are some of the largest recent moves:
以下是一些最近最大的交易動態：
- ARTAL GROUP S.A. removed 1,819,884 shares (-100.0%) from their portfolio in Q3 2024
- DEEP TRACK CAPITAL, LP added 1,578,749 shares (+410.3%) to their portfolio in Q3 2024
- BVF INC/IL removed 710,276 shares (-17.4%) from their portfolio in Q3 2024
- ASSENAGON ASSET MANAGEMENT S.A. removed 679,514 shares (-39.2%) from their portfolio in Q3 2024
- SUVRETTA CAPITAL MANAGEMENT, LLC added 583,155 shares (+8.2%) to their portfolio in Q3 2024
- SOFINNOVA INVESTMENTS, INC. removed 528,359 shares (-64.0%) from their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC added 505,712 shares (+149.0%) to their portfolio in Q3 2024
- ARTAL GROUP S.A.在2024年第三季度將1,819,884股股票（-100.0%）從其投資組合中移除
- DEEP TRACk CAPITAL, LP在2024年第三季度將1,578,749股股票（+410.3%）添加到其投資組合中
- BVF INC/IL在2024年第三季度將710,276股股票（-17.4%）從其投資組合中移除
- ASSENAGON資產管理SA在2024年第三季度將679,514股股票（-39.2%）從其投資組合中移除
- SUVRETTA CAPITAL MANAGEMENt, LLC在2024年第三季度將583,155股股票（+8.2%）添加到其投資組合中
- SOFINNOVA INVESTMENTS, INC.在2024年第三季度將528,359股股票（-64.0%）從其投資組合中移除
- MILLENNIUm MANAGEMENt LLC在2024年第三季度將505,712股股票（+149.0%）添加到其投資組合中
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
要追蹤對沖基金的股票組合，請查看Quiver Quantitative的機構持股儀表板。
Full Release
全面發佈
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual investor event at 8:00 a.m. ET / 5:00 a.m. PT on Monday, December 9, 2024, to discuss the KOMET-007 combination trial of the Company's oral and selective menin inhibitor, ziftomenib, following the presentation of updated clinical data at the 66
th
American Society of Hematology (ASH) Annual Meeting in San Diego.
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual investor event at 8:00 a.m. Et / 5:00 a.m. Pt on Monday, December 9, 2024, to discuss the KOMEt-007 combination trial of the Company's oral and selective menin inhibitor, ziftomenib, following the presentation of updated clinical data at the 66
樓
American Society of Hematology (ASH) Annual Meeting in San Diego.
The virtual event will feature members of the management team along with investigators from the KOMET-007 trial. The live call may be accessed by dialing (800) 715-9871 for domestic callers and (646) 307-1963 for international callers and entering the conference ID: 4326549. A live webcast will be available
here
and in the Investors section of Kura's website, with an archived replay available shortly after the event.
The virtual event will feature members of the management team along with investigators from the KOMEt-007 trial. The live call may be accessed by dialing (800) 715-9871 for domestic callers and (646) 307-1963 for international callers and entering the conference ID: 4326549. A live webcast will be available
這裏
and in the Investors section of Kura's website, with an archived replay available shortly after the event.
About Kura Oncology
關於kura oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). In November 2024, Kura entered a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed and the companies anticipate submission of a New Drug Application in 2025. Kura is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura's website at
and follow us on
X
and
LinkedIn
.
kura oncology是一家臨床階段的生物製藥公司，致力於實現癌症治療的精準藥物的承諾。該公司的產品線包括針對癌症信號通路的小分子藥物候選。Ziftomenib是一種每日一次的口服menin抑制劑，是第一款並且唯一一款正在進行研究的療法，獲得了美國食品和藥物管理局針對復發/難治性（R/R）NPM1基因突變急性髓樣白血病（AML）治療的突破性療法認定。2024年11月，Kura與協和鳴人株式會社達成全球戰略合作協議，共同開發和商業化ziftomenib用於AML和其他血液惡性腫瘤。在復發/難治性NPM1突變AML中ziftomenib的2期註冊導向試驗招募已經完成，公司預計將於2025年提交新藥申請。Kura還在進行一系列臨床試驗，評估ziftomenib與目前治療標準聯合治療新診斷和復發/難治性NPM1突變和KMT2A重排AML。KO-2806是一種次世代法尼酰轉移酶抑制劑，正在評估其在1期劑量遞增試驗中作爲單藥治療以及與靶向治療聯合使用。Tipifarnib是一種有效且選擇性的FTI，目前正在與alpelisib聯合進行1/2期試驗，用於PIK3CA依賴性頭頸鱗狀細胞癌患者。有關更多信息，請訪問Kura的網站：
並關注我們
X
和
LinkedIn
.
Kura Contacts
kura oncology 聯繫人
Investors:
Pete De Spain
Executive Vice President, Investor Relations &
Corporate Communications
(858) 500-8833
pete@kuraoncology.com
投資者:
Pete De Spain
執行副總裁，投資者關係
企業通訊
858-500-8833
pete@kuraoncology.com
Media:
Cassidy McClain
Vice President
Inizio Evoke Comms
(619) 849-6009
cassidy.mcclain@inizioevoke.com
媒體:
Cassidy McClain
副總裁
Inizio Evoke Comms
(619) 849-6009
cassidy.mcclain@inizioevoke.com